Robert J Chilton
Division of Cardiology, The University of Texas Health Science Center at San Antonio,
7703 Floyd Curl Drive, San Antonio, Texas 78229
Tanzania
Review Article
Potential Cardiovascular Effects of the Glucagon-like Peptide-1 Receptor Agonists
Author(s): Robert J ChiltonRobert J Chilton
In patients with type 2 diabetes, cardiovascular risk reduction represents an important clinical goal in light of the elevated risk of cardiovascular mortality in this patient population; thus, it is important that glucose-lowering drugs have no negative effects and potentially some positive effects on cardiovascular risk. The glucagon-like peptide-1 receptor agonists (GLP-1RAs), which were designed to resist degradation by the enzyme dipeptidyl peptidase-4, are among the newer glucose-lowering agents for the treatment of type 2 diabetes. There are a number of agents within this class, including exenatide, liraglutide, albiglutide, lixisenatide, and dulaglutide. Preclinical research efforts in animal models have identified a number of favorable cardiovascular effects of GLP-1RAs beyond glucose lowering. Although the underlying basis for these cardiovascular effects ha.. View More»
